Pharmacometabolomics Applied to Personalized Medicine in Urological Cancers.

Amaro, Filipa; Carvalho, Márcia; Bastos, Maria de Lourdes; Guedes de Pinho, Paula; Pinto, Joana

Amaro, Filipa; Carvalho, Márcia; Bastos, Maria de Lourdes; Guedes de Pinho, Paula; Pinto, Joana.

Afiliación

Amaro F; Associate Laboratory i4HB-Institute for Health and Bioeconomy, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
Carvalho M; UCIBIO/REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
Bastos ML; Associate Laboratory i4HB-Institute for Health and Bioeconomy, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
Guedes de Pinho P; UCIBIO/REQUIMTE, Department of Biological Sciences, Laboratory of Toxicology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal.
Pinto J; FP-I3ID, FP-ENAS, CEBIMED, University Fernando Pessoa, 4200-150 Porto, Portugal.

Pharmaceuticals (Basel) ; 15(3)2022 Feb 28.

Article en En | MEDLINE | ID: mdl-35337093

Palabras clave

biomarkers; bladder cancer; pharmacometabolomics; prostate cancer; renal cell carcinoma; treatment response

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies Idioma: En Revista: Pharmaceuticals (Basel) Año: 2022 Tipo del documento: Article País de afiliación: Portugal Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google